---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-018553"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T08:21:41.721029+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q4 revenue $19.7M (-3% YoY); guides FY23 revenue growth at least 10%

## Summary
- Q4 revenue $19.7M (-3% YoY), gross profit $12.5M (+1%), GAAP net loss $0.3M ($0.02 loss per share).
- Non-GAAP net income $4.4M ($0.25 per diluted share).
- FY22 revenue up 2%, generated $10.7M cash from ops, repurchased 1.2M shares at avg $16.49.
- Exited 2022 with six RWD-AI deals; pipeline of several dozen.
- FY23 guidance: revenue growth at least 10% YoY, gross margin 58-62%; Q1 revenue $11.5-13M.

## SEC filing metadata
- accession: 0001213900-23-018553
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/0001213900-23-018553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/ea174846-8k_optimizerx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-018553
- JSON: https://secwatch.observer/filing/0001213900-23-018553.json
- Plain text: https://secwatch.observer/filing/0001213900-23-018553.txt

## Key facts
- Earnings Releases
  OptimizeRx Corp reported the fourth quarter and year ended December 31, 2022 results: revenue $19.7 million, net income GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share, EPS $(0.02) per basic and diluted share. Guidance initiated.
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $19.7 million
  - Net income: GAAP net loss totaled $(0.3) million or $(0.02) per basic and diluted share
  - EPS: $(0.02) per basic and diluted share
  - Guidance: initiated
  - Result: preliminary results
  source text: 2 ea174846ex99-1_optimizerx.htm PRESS RELEASE, DATED MARCH 8, 2023 Exhibit 99.1 OptimizeRx Reports Fourth Quarter and Full Year 2022 Financial Results - Q4 revenue of $19.7 million, down 3% year-over-year and up 30% quarter-over-quarter - Q4 gross profit increased 1% year-over-year to $12.5 million as gross margins increased from 61% to 63% -
  evidence_url: https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/0001213900-23-018553-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.